Recent 8-K filings for PROF
Highest-materiality recent filing
Profound Medical Reports Strong Q1 2026 Results with 104% Revenue Growth and Humana Coverage
- Revenue grew 104% year-over-year to $5.3M, with $2.5M recurring and $2.9M capital equipment.
- Net loss improved 34% to $7.0M ($0.19 per share) from $10.7M in Q1 2025.
-
Revenue $2.5M, up 12% YoY; $3.1M of TULSA shipments shifted to Q3 due to logistics, resolved.
-
CAPTAIN trial: TULSA preserves penile length vs 0.65 cm loss with robotic RP at 1 month
No median change in penile length at 1 month for TULSA vs 0.65 cm reduction for robotic RP.
-
Profound Medical Reports Strong Q1 2026 Results with 104% Revenue Growth and Humana Coverage
Revenue grew 104% year-over-year to $5.3M, with $2.5M recurring and $2.9M capital equipment.
-
CAPTAIN trial meets primary safety endpoint: TULSA superior to robotic RP on function preservation
Primary composite endpoint met: 50% of TULSA patients preserved erectile function and continence at 6 months vs 24% for RP (p<0.05, risk ratio 2.1).
-
Profound Medical to present first CAPTAIN trial outcomes at EAU 2026, host investor call March 13
First CAPTAIN trial outcomes (TULSA vs radical prostatectomy) presented at EAU 2026 on March 13 at 9:40 a.m. EDT.
-
Profound Medical Q4 revenue $6M (+43% YoY), net loss $8.2M; installed base 78 TULSA-PRO
Q4 revenue record $6.0M (+43% YoY); net loss $8.2M ($0.27/sh) vs $4.9M loss year ago.
-
Mount Sinai treats first prostate cancer patient with Profound's TULSA-PRO system
Mount Sinai Hospital (ranked #6 for Urology) is first in Metro New York to offer TULSA-PRO incision-free, MRI-guided prostate treatment.
-
Profound Medical TULSA-PRO installed base reaches 78 systems, exceeding 2025 target of 75
TULSA-PRO installed base stood at 78 systems as of Dec. 31, 2025, above the goal of 75.
-
Johns Hopkins Hospital treated its first non-clinical-trial prostate cancer patient using Profound's TULSA-PRO system.
-
Sold 5,142,870 common shares at $7.00 each in registered direct offering; gross proceeds ~$36M.
-
Launched TULSA-AI Volume Reduction module for BPH at RSNA; reduces procedure times and enables same-day stacking.
-
Profound Medical signs exclusive distribution deal for TULSA-PRO in Australia, New Zealand
Exclusive distribution & supply agreement with Getz Healthcare for TULSA-PRO system in Australia and New Zealand.
-
Profound Medical reports preliminary Q3 revenue $5.2-5.3M, up 84-87% YoY
Preliminary unaudited Q3 2025 revenue of $5.2-5.3M vs $2.8M in Q3 2024, growth 84-87%.
-
Net loss of $15.7M ($0.52/share) vs $6.9M ($0.28/share) in Q2 2024; revenue unchanged at $2.2M.
-
Profound Medical Q1 2025 revenue $2.6M (+82% YoY); net loss $10.7M vs $6.6M
Revenue $2.6M, up 82% from $1.4M in Q1 2024; gross margin 71% vs 60%.
-
CAPTAIN RCT peri-operative data: median blood loss 0 vs 100 mL and length of stay 0.29 vs 1.24 days for TULSA vs robotic prostatectomy (p<0.001).
-
CAPTAIN trial: TULSA shows zero blood loss, shorter stay vs robotic prostatectomy (p<0.001)
Median blood loss 0 mL (TULSA) vs 100 mL (RP); length of stay 0.29 vs 1.24 days (p<0.001).
-
Profound Medical restates Q1-Q3 2024 financials due to $472k revenue error; Q4 revenue up 108% YoY
Revenue overstated by $472k in Q1 2024; prior 6-K filings for Q1-Q3 2024 no longer reliable.
-
Profound Medical Q4 revenue up ~105-110% YoY; switches to US GAAP
Preliminary Q4 2024 revenue $4.1-4.2M, YoY growth 105-110%, sequential growth 45-48%.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.55 · Most common event other_material